HotSpot debuts with $45M to find, drug natural allosteric sites

HotSpot Therapeutics Inc. (Cambridge, Mass.) emerged from stealth on Tuesday with a $45 million series A round co-led by Atlas Venture and Sofinnova Partners. The company is developing small molecule therapies that imitate natural forms of allosteric regulation, which could open up targets that are not druggable via traditional active site-directed approaches.

While other companies have used computational and chemical screening platforms to identify allosteric therapies, HotSpot is the first to use a systematic method to identify and drug natural allosteric sites...